Articles by Mollie Shields-Uehling

Mollie Shield-Uehling directs the business and strategic activities of SAFE-BioPharma Association and serves as the primary liaison with member companies, vendor partners and others in the growing SAFE-BioPharma community. She is a member of the association’s Board of Directors.

Ms. Shields-Uehling has more than 20 years of international trade and biopharmaceutical industry experience. Prior to joining SAFE-BioPharma Association, Ms. Shields-Uehling was principal of Shields-Uehling Associates, an international public affairs consultancy. She previously served in various leadership positions with Bristol-Myers Squibb, Wyeth, the International AIDS Vaccine Initiative (IAVI), and in the White House Office of the U.S. Trade Representative and the U.S. Foreign Commercial Service. She has been recognized by PharmaVOICE Magazine as one of the pharmaceutical industry’s most influential leaders.  

SAFE-BioPharma
SAFE-BioPharma® was developed by a consortium of biopharmaceutical and related companies, with participation from the US Food and Drug Administration and the European Medicines Agency. www.safe-biopharma.org

Association members include Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Forest Laboratories, Johnson & Johnson, Eli Lilly, Merck, Pfizer,  Roche, and Sanofi-Aventis.

SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.